Medication info

Lepirica Capsule 25 mg (Pregabalin)

Prescription medicationHard capsuleOralExpired
Ingredient · strength
Pregabalin›25mg / 1 capsule
Manufacturer / importer
Boryung Biopharma Co., Ltd.
Appearance
Hard capsule with a pale yellow upper part and white lower part containing white powder
Packaging
30 capsules/bottle
Approval status
Expired

MFDS item code 202000754 · Approved 2020.02.10

This product's status changed to Expired on 2025.02.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Because this medicine is eliminated mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is eliminated mainly by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (mg/dL) * For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1] Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the method of administration. b: The supplemental dose is a dose administered once in addition. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years or older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Boryung Biopharma Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This drug is used to relieve pain due to peripheral and central nervous system disorders in adults. It is also effective as an adjunctive therapy for partial seizures in epilepsy patients. It helps relieve pain caused by fibromyalgia. It plays an important role in improving symptoms for patients with various neurological disorders.

How to take

Adult dose

This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Because this medicine is eliminated mainly by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is eliminated mainly by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (mg/dL) * For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1] Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Initial dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the method of administration. b: The supplemental dose is a dose administered once in addition. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years or older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This drug may increase the risk of suicidal thoughts or behaviors, so if mood changes or depressive symptoms occur while taking this medication, the patient must inform their doctor immediately. Patients with allergies to any ingredients or certain genetic metabolic issues should not take this medication. Diabetic patients may require adjustments to their blood sugar control medications due to potential weight gain, so caution is advised. If severe allergic reactions like angioedema occur, the medication must be stopped immediately. Elderly patients should be particularly careful when first taking the medication due to the risk of dizziness or drowsiness leading to falls. Visual disturbances such as blurred vision may occur. If symptoms persist, consult a physician. Abruptly stopping the medication can lead to withdrawal symptoms such as insomnia, headaches, and anxiety, so the dosage should be gradually reduced under a doctor's guidance. There is a risk of drug abuse; therefore, patients with a history of substance use should take this medication with extra caution. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should take this medication with caution. Since it has central nervous system depressant effects, drowsiness or confusion may occur when taken with alcohol or other sedatives, so extra caution is needed. Pregnant women or those planning to become pregnant must consult their physician about the potential effects on the fetus and use effective contraception. Breastfeeding women should consider stopping breastfeeding or discontinuing the medication, as it may be transmitted through breast milk. It is advisable to avoid activities that require concentration, such as driving or operating machinery, until changes in symptoms are confirmed after taking the medication. In case of overdose, symptoms such as drowsiness, confusion, and seizures may occur, requiring an immediate medical visit, and treatment such as hemodialysis may be necessary. Store out of reach of children and do not transfer to other containers, for safety. If severe rash or allergic symptoms occur on the skin, the medication should be stopped immediately, and healthcare personnel should be consulted.

Side effects

  • suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • swelling around the mouth
  • upper respiratory swelling
  • dizziness
  • drowsiness
Show 184 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal thoughts
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • impaired respiratory function
  • respiratory diseases
  • neurological disorders
  • renal impairment
  • rhinitis
  • neutropenia
  • increased appetite
  • anorexia
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • paraphilia
  • agitation
  • mood lability
  • emotional blunting
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • movement coordination disorders
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • speech impairment
  • sensory abnormalities
  • sensory loss
  • sedation
  • drowsiness syndrome
  • cognitive impairment
  • nystagmus
  • language disorders
  • myoclonus
  • reflex reduction
  • movement disorders
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • action tremor
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing impairment
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree heart block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory impairment
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urine output
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • sensory abnormalities
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • agitation
  • restlessness
  • exacerbation of seizures
  • shock
  • anaphylaxis-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a sealed container to protect it from air and moisture, maintaining a storage temperature between 15 and 30 degrees Celsius (room temperature). By keeping the appropriate temperature and container condition, the effectiveness of the drug can be preserved safely for a long time.

Appearance and packaging

Appearance

Hard capsule with a pale yellow upper part and white lower part containing white powder

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.